Achieve Life Sciences develops cytisinicline, a drug candidate intended to help people quit smoking or vaping. ACHV reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 30 | Stifel | Initiated | Buy | |
| Aug 13 | Morgan Stanley | Initiated | Buy | |
| Jun 22 | HC Wainwright & Co. | Reiterated | Buy | |
| Apr 21 | Canaccord Genuity | Initiated | Buy |
Seasonality
How ACHV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ACHV in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACHV is in one of them and how their past ACHV trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACHV in an article yet. Here's the latest on the wider market.
About Achieve Life Sciences
Achieve Life Sciences is a specialty pharmaceutical company based in Seattle, Washington. It is developing cytisinicline, a drug candidate for treating nicotine dependence in people who want to quit smoking or vaping. The drug has not yet been approved by U.S. regulators. Its target customers are adult smokers and vapers, and the company also holds rights to commercialize the drug in regions outside a European partner's territory.
- Headquarters
- Seattle, WA